Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice
This large-scale, prospective, real-world study demonstrated a long OS, comparable to that reported in the global Phase III REFLECT trial. More advanced-stage tumors and worse hepatic function have been suggested as OS-associated factors, consistent with previous reports.
Authors
- Yasuteru Kondo (ORCID: https://orcid.org/0000-0001-5935-4346)
- Kenta Motomura (ORCID: https://orcid.org/0000-0002-7515-099X)
- Katsuaki Motoyoshi
- Masatoshi Kudo (ORCID: https://orcid.org/0000-0002-4102-3474)
- Yoshitaka Inaba (ORCID: https://orcid.org/0000-0002-0850-6327)
- Junji Furuse (ORCID: https://orcid.org/0000-0003-0663-6117)
- Namiki Izumi (ORCID: https://orcid.org/0000-0002-0055-8229)
- Kazuhisa Yabushita
- Yoshio Katamura
- Toshiyuki Matsuoka (ORCID: https://orcid.org/0000-0003-3583-2993)
Institutions
- Kanagawa Prefectural Hospital Organization (JP)
- Sapporo Higashi Tokushukai Hospital (JP)
- Fukuyama City Hospital (JP)
- Aichi Cancer Center (JP)
- Aso Iizuka Hospital (JP)
- Musashino Red Cross Hospital (JP)
- Onomichi General Hospital (JP)
- Kanagawa Cancer Center
- Sendai Tokushukai Hospital
- Eisai (Japan) (JP)
- Kindai University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-01
- DOI
- https://doi.org/10.3390/cancers17030479
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Eisai